New analyses of oral Otezla® (apremilast) show efficacy in difficult-to-treat areas of moderate to severe plaque psoriasis

Celgene International Sàrl has presented results from additional efficacy and safety analyses of OTEZLA® (apremilast) from the ESTEEM phase III clinical trial programme at the 23rd European...